A phase III study of Amantadine (ADS-5102) for the treatment of multiple sclerosis (MS).
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2016
At a glance
- Drugs Amantadine (Primary)
- Indications Movement disorders; Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Adamas Pharmaceuticals
- 15 Jan 2016 New trial record
- 12 Jan 2016 According to a media release of Adamas pharmaceuticals, this trial will initiate in 2017.